Elsevier

Health Policy

Volume 91, Supplement 1, July 2009, Pages S15-S25
Health Policy

Original article
Smoking cessation: How compelling is the evidence? A review

https://doi.org/10.1016/S0168-8510(09)70004-1Get rights and content

Abstract

Objectives

To provide a short review of the evidence base supporting smoking cessation interventions, including behavioral therapy and pharmacological treatment options.

Methods

Published meta-analysis was mainly used supplemented with a limited literature search.

Results

Effective smoking cessation consists of pharmacotherapy and behavioral support. Counseling increases abstinence rates parallel to the intensity of support. First-line pharmacological drugs for smoking cessation are nicotine replacement products (patch, gum, inhaler, nasal spray, lozenge/tablets), varenicline and bupropion SR with scientific well-documented efficacy when used for 2-3 months and mostly mild side effects. Alternative therapies such as hypnosis and acupuncture have no scientifically proven effects.

Conclusions

With the most optimal drugs and counseling today a 1-year abstinence rate of approximately 25% can be expected in smoking cessation. On-going research is examining the potential effects of nicotine vaccination as relapse prevention.

Introduction

In this review the main focus will be on first-line medications for smoking cessation. It is mainly based on Cochrane meta-analysis and the meta-analysis in the US guidelines updated in 2008. Relevant other papers will be used to illustrate specific areas of clinical importance based on the author's experience (clinic and research) in this field for more than 20 years. The purpose is to provide the clinician with an-up-to date overview of this area.

Cigarette smoking is a chronic relapsing disease. It is defined in ICD-10, the International Classification System of Diseases from the World Health Organization (WHO) [1]. One of the most important reasons for long-term smoking is dependence on nicotine in tobacco although psychological components, habituation and genetic influences also are involved 2, 3. Specific nicotine receptors have been identified in the brain, and after destruction of these receptors in nicotine-addicted rats, they will stop their nicotine intake. When nicotine binds to these receptors dopamine is released, which is believed to be associated with the acute rewarding effect of nicotine 4, 5. However, the biochemical basis for nicotine dependence seems to be far more complex and involve several other mechanisms and mediators as dealt with in detail in review papers [4].

As with other addictions such as heroin and cocaine abuse, a smoker often has to quit several times before becoming a permanent ex-smoker. The relapse after smoking cessation is highest during the first 3-6 weeks and then gradually declines [6].

A typical abstinence curve is illustrated by the results from a large smoking cessation study with varenicline (Fig. 1)[7]. With adequate support and pharmacological therapy it is possible to achieve an initial quit rate of approximately 50-60% during the first 3 months in the so-called "cessation period". From 3 months up to 12 months almost half of the subjects relapse to smoking in the so-called "relapse period", ending up with a 1-year quit rate around 25-35% 6, 7, 8.

To stop smoking requires breaking a complex habit and addiction. To achieve reasonable quit rates, it is necessary to administer support combined with pharmacological drugs [8].

Thus, tobacco smoking can be regarded as a chronic, recurrent disorder with an expected successful cessation rate with optimal treatment of 15-35% after 1 year, similar to other addictive disorders. Several failed cessation attempts may occur before permanent abstinence is achieved.

Section snippets

Evidence for smoking cessation: different support modes

Several high quality meta-analyses have been performed in this area examining different interventions for smoking cessation including the Cochrane Database, the Fiore AHCPR (US Agency for Healthcare Policy and Research) publication from US, and NICE (National Institute for Clinical Excellence) guidelines from UK plus several others 6, 7, 8, 9, 12, 13, 14. Starting with the most minimal intervention, i.e. self-help materials for smoking cessation, an unsurprisingly low 1% increase in quit rate

Evidence for smoking cessation: pharmacological therapies

The rationale for pharmacological therapies is that, when quitting smoking, the administration of the cessation drug decreases withdrawal symptoms in the first months, thus allowing the subject to cope with the behavioral and psychological aspects of smoking.

Older agents such as clonidine and nortriptyline are effective but they are regarded as second-line drugs due to their side effects [8].

Nicotine replacement therapy (NRT), varenicline and bupropionSR are regarded first-line medications 8, 12

Evidence for smoking cessation: Other therapies

Other frequently used interventions are acupuncture and hypnosis, negative effects and cue exposure (i.e. exposing smokers to smoking cues without the opportunity to smoke). However, the evidence does not support an effect from these alternative therapies. A meta-analysis comparing active versus control acupuncture found that acupuncture was no more effective than placebo 37, 38. One study has been published using laser therapy in 320 adolescents, and did not demonstrate any effect, with a 3

Cost-effectiveness

From a large prospective study of English male doctors followed for 40 years it was found that the relative risk for death was 1.8 for smokers compared to never smokers, with an annual mortality rate per 100,000 of 1.6 for coronary heart disease, 12.6 for COPD and 14.9 for lung cancer [42] (Table 3).

Updated data calculating mortality from smoking in developed countries during 1950-2000 have been published. The health problem of smoking is large; in the 25 countries that were members of the EU

Model study in smoking cessation

The Lung Health Study I (LHS) is an exemplary smoking cessation model study (Fig. 3). The LHS was a multi-centre randomized study of smoking intervention versus usual care, also testing an inhaled anti-cholinergic bronchodilator. A total of 5,887 subjects with mild COPD [i.e. a mean FEVi of 75% predicted, 2.7 L (SD 0.6 L)] were enrolled in the study. They had a mean age of 48 years with a smoking history of 40 pack-years [44]. During the first 3 months an intensive 12-session smoking cessation

Nicotine vaccination

Smokers have no antibodies to nicotine as it is a small molecule. The rationale for nicotine vaccination is that the vaccine (nicotine bound to a hapten) will induce antibodies against nicotine, and as the nicotine from tobacco is bound in the blood by these antibodies, less nicotine will reach the brain. Phase I and II studies have evaluated 3 different vaccines, NicVAX, NICQb, and TA-NIC 58, 59, 60. Dosing has been 2-6 injections with an interval of 2-4 weeks and a later booster dose. Marked

Conclusions

In 25 EU countries and in the United States, the annual excess deaths due to smoking reach 655,000 and 512,000, respectively. An annual increase in relative mortality of 1.8 is expected in smokers compared to never-smokers. Smoking cessation interventions are very cost-effective with a cost of €400–1,500 per QALY gained. NRT, varenicline and bupropionSR have scientific, well-documented efficacy in smoking cessation. Combination with counseling increases abstinence rates parallel to the

References (64)

  • V Batra et al.

    The genetic determinants of smoking

    Chest

    (2003)
  • JE Anderson et al.

    Treating tobacco use and dependence: an evidence-based clinical practice guideline for tobacco cessation

    Chest

    (2002)
  • C Cohen et al.

    CB(1) receptor antagonists for the treatment of nicotine addiction

    Pharmacology Biochemistry and Behavior

    (2005)
  • World Health Organization

    International Classification of Diseases

    (1992)
  • US Department of Health and Human Services

    Nicotine addiction. A report of the Surgeon General

    (1998)
  • American Psychiatric Association

    Diagnostic and statistical manual of mental disorders

    (1994)
  • SS Watkins et al.

    Neural mechanisms underlying nicotine addiction: acute positive reinforcement and withdrawal

    Nicotine and Tobacco Research

    (2000)
  • C Silagy et al.

    Nicotine replacement therapy for smoking cessation. Cochrane Database of Systematic Reviews, Issue 1, 2006

  • D Gonzales et al.

    Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial

    Journal of the American Medical Association

    (2006)
  • MC Fiore et al.

    Clinical Practice Guideline. Treating Tobacco use and Dependence: 2008 Update

    (May 2008)
  • R West et al.

    Smoking cessation guidelines for health professionals: an update

    Thorax

    (2000)
  • DE Jorenby et al.

    Efficacy of varenicline, an a4, b2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation

    Journal of the American Medical Association

    (2006)
  • S Tonstad et al.

    Effect of maintenance therapy with varenicline on smoking cessation

    Journal of the American Medical Association

    (2006)
  • National Institute for Clinical Excellence (NICE)

    Guidance on the use of nicotine replacement therapy (NRT) and bupropion for smoking cessation. National Institute for Clinical Excellence Technology Appraisal Guidance No. 39, Apr 2002

  • JR Hughes et al.

    The American Psychiatric Association Practice Guidelines for the treatment of patients with nicotine dependence

    American Journal of Psychiatry

    (1996)
  • T Lancaster et al.

    Self-help interventions for smoking cessation. The Cochrane Library Oxford: Update Software, 2002

  • R Borland et al.

    The effectiveness of personally tailored computer generated advice letters for smoking cessation

    Addiction

    (2004)
  • P Aveyard et al.

    A controlled trial of an expert system and self help manual interventions based on the stages of change versus standard help materials in smoking cessation

    Addiction

    (2003)
  • E Lichtenstein et al.

    Telephone counseling for smoking cessation: rationales and meta-analytic review of evidence

    Health Education Research

    (1996)
  • R Borland et al.

    The effectiveness of callback counselling for smoking cessation: a randomised trial

    Addiction

    (2001)
  • ZR Macleod et al.

    Telephone counselling as an adjunct to nicotine patches in smoking cessation: a randomised controlled trial

    Medical Journal of Australia

    (2003)
  • LF Stead et al.

    Telephone counselling for smoking cessation

    Cochrane Database of Systematic Reviews

    (2003)
  • T Lancaster et al.

    Physician advice for smoking cessation

    Cochrane Database of Systematic Reviews

    (2004 Oct 18)
  • V Rice et al.

    Nursing interventions for smoking cessation

    Cochrane Database of Systematic Reviews

    (2004)
  • T Lancaster et al.

    Individual behavioural counselling for smoking cessation. The Cochrane Library

    (2002)
  • LF Stead et al.

    Group behaviour therapy programmes for smoking cessation

    Cochrane Database of Systematic Reviews

    (2002)
  • A Hjalmarson et al.

    Effect of nicotine nasal spray on smoking cessation

    Archives of Internal Medicine

    (1994)
  • A Hjalmarson et al.

    The nicotine inhaler in smoking cessation: a double-blind randomised clinical evaluation

    Archives of Internal Medicine

    (1997)
  • Hjalmarson A. Smoking Cessation. Evaluation of supportive strategies with special reference to nicotine replacement...
  • P Tønnessen et al.

    Higher dosage nicotine patches increase one-year smoking cessation rates: results from the European CEASE-trial

    European Respiratory Journal

    (1999)
  • L Schmølker

    A review of the evidence for long-term use of Nicotine Replacement Therapy (NRT), Master thesis

    (30 June 2005)
  • S Shiffman et al.

    Real-world efficacy of prescription and over-the-counter nicotine replacement therapy

    Addiction

    (2002)
  • Cited by (0)

    View full text